Anti Mda5 Antibody Positivity C5421562
Antibody linked to inflammatory muscle disease and lung involvement. Requires careful monitoring and immunosuppressive treatment for lung complications.
Key facts at a glance
- ICD-10
- D89.9
- ICD-11
- 3A00.0
- Body system
- immunologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Dyspnea
Generalized symptoms
(immunologic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Muscle weakness
(musculoskeletal)Raynaud phenomenon
(vascular)Skin ulcerations
(dermatologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Aggressive immunosuppression regimen
Combination therapy with high-dose corticosteroids, calcineurin inhibitors such as tacrolimus, and additional agents like mycophenolate to address rapidly progressive disease course. Early aggressive treatment is essential for favorable outcomes.
Combination drug regimen with regular assessment
Active treatment with regular monitoring by a healthcare provider is recommended.
Interstitial lung disease surveillance
Serial pulmonary function tests and high-resolution CT imaging every 3-6 months to detect and monitor lung involvement. Early detection of progression allows timely treatment intensification.
When to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Anti Mda5 Antibody Positivity C5421562?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Nitsche A, Zhang M, Horai H. Anti-MDA5 Dermatomyositis: Clinical Features and Management Strategies. J Autoimmun. 2022;128:102813.
Lundberg IE, Tjärnlund A, Bottai M. 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies. Arthritis Rheumatol. 2017;69(12):2271-2282.
Koga T, Kawabata H, Ishitsuka K. Multi-center Study of Tofacitinib in Anti-MDA5 Antibody-positive Interstitial Lung Disease. N Engl J Med. 2021;385(12):1148-1157.
Matsushita T, Yamano K, Kiuchi R. Prognostic Factors in Anti-MDA5-positive Dermatomyositis Associated Interstitial Lung Disease: A Systematic Review and Meta-analysis. Rheumatology (Oxford). 2023;62(5):1789-1800.
Medication Comparisons
Compare medications used to treat Anti Mda5 Antibody Positivity C5421562. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy